Sepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™

The global sepsis diagnostics market is projected to grow from $0.83 billion in 2026 to $1.22 billion by 2031, a 7.9% CAGR, supported by demand for faster molecular pathogen detection, antimicrobial-susceptibility testing and biomarker-based diagnostics. North America held 43.2% of the market in 2025, while hospitals and specialty clinics represented 62.7% and assays, kits and reagents accounted for 40.7%. Funding and M&A activity remain supportive, including Cytovale's $100 million Series D and Bruker's approximately $29.4 million acquisition of AST Revolution, although bioMérieux's €141 million VITEK REVEAL impairment highlights slower-than-expected commercial adoption risks.

Analysis

This is not a material near-term demand surprise for diversified diagnostics incumbents: sepsis is too small a revenue pool to alter DHR, TMO, RHHBY/Roche, BDX, or A estimates absent evidence of incremental hospital test utilization. The relevant equity mechanism is mix: recurring microbiology consumables carry better revenue durability than instrument placements, while embedded sepsis markers may defend installed analyzer fleets without creating meaningful standalone revenue. Treat the market-growth estimate as vendor-sponsored directional context, not a catalyst.

BRKR has the clearest asymmetric strategic exposure because direct-from-blood metagenomics, host-DNA depletion, and rapid susceptibility testing could displace portions of the traditional culture-to-identification workflow. The upside is 6-18 months away and depends on clinical validation, reimbursement, and lab workflow economics; hospitals will not pay for faster turnaround merely because the technology is superior unless it demonstrably reduces ICU days or broad-spectrum antibiotic use. BDX is more exposed to workflow substitution at the blood-culture layer, although its installed base and consumables annuity make displacement gradual rather than binary.

The contrarian read is that rapid sepsis diagnostics remain adoption-constrained, not technology-constrained. Recent impairment evidence across the industry suggests sales cycles, utilization, and evidence generation matter more than headline market growth; this favors scaled incumbents with service infrastructure over venture-backed disruptors in the next 12 months. Watch hospital capital budgets, CMS/reimbursement developments, and disclosed diagnostic-segment organic growth for confirmation; a sustained deterioration in microbiology consumable growth would falsify the installed-base resilience thesis.

WAT's combination with BD assets is principally an execution and separation trade, not a sepsis-growth trade. If integration costs or customer disruption emerge, WAT could face multiple compression before any cross-selling benefit is visible; conversely, clean closing and synergy targets can provide a 3-9 month catalyst independent of underlying sepsis demand.

Key Decisions for Investors

• No broad diagnostics-sector trade on this release: require quarterly evidence of accelerated consumables utilization or raised infectious-disease guidance before adding DHR, TMO, BDX, or A.
• Maintain a 6-18 month tactical long bias in BRKR versus BDX, sized modestly: BRKR has higher upside to successful commercialization of culture-independent workflows, while BDX is the cleaner legacy-workflow hedge. Exit if BRKR reports delayed clinical adoption, material dilution, or subscale life-science organic growth; avoid entering after a sharp acquisition-driven rerating.
• Use WAT as an event-driven watch item into transaction milestones over the next 3-9 months. Consider long WAT only after regulatory clearance and quantified synergy/cost disclosures; downside risk is separation complexity and a weaker-than-expected diagnostic-assets growth profile.
• Monitor BIM/bioMerieux results for reagent-growth and rapid-AST utilization as the best public read-through on real hospital adoption. A sequential slowdown in consumables or further impairment/restructuring would support the view that rapid-sepsis penetration is being overestimated.